From JPMA Efforts to Countermeasures Against New Coronavirus Infections In response to the declaration of a state of emergency

Following the declaration of a state of emergency in January 2021, the Pharmaceutical Manufacturers Association of Japan (PMAJ) has issued the following message to reaffirm its position and efforts as an industry.

We will continue to work on appropriate communication in light of the situation of the spread of the new coronavirus.

The spread of the new coronavirus continues, and even today, many people are infected and many irreplaceable lives have been lost. Under these circumstances, I would like to express my heartfelt gratitude to all those who are doing their utmost to fight the virus every day, including medical professionals, and to all those who carry out essential tasks in our daily lives.

As a member of the Pharmaceutical Manufacturers Association of Japan (PMAJ), we, the pharmaceutical companies, are in a position to contribute to the nation's healthcare through research, development, and stable supply of pharmaceuticals, and in response to the emergency declaration issued on January 7, 2021 for Tokyo, Saitama, Chiba, and Kanagawa prefectures, we are committed to further efforts and promotion of the following items related to measures against the new type of coronavirus infection In response to the declaration of a state of emergency in Tokyo, Saitama, Chiba, and Kanagawa prefectures, we will make further efforts to promote the following matters

Based on the recognition that the rapid research and development of safe and effective drugs and vaccines is an important means of bringing the situation under control, pharmaceutical association member companies will continue to work diligently to deliver safe and effective drugs and vaccines for infectious diseases to those who need them.

In order to ensure that the treatment of all diseases is not delayed in the midst of a tight medical situation, the member companies of the Pharmaceutical Manufacturers Association of Japan (PMMA) will continue to supply necessary drugs and provide appropriate information to medical institutions and others.

The spread of infectious diseases has caused temporary suspensions or delays in clinical trials for new drugs needed in areas other than infectious diseases. The member companies of the Pharmaceutical Manufacturers Association of Japan (PMAJ) will continue to make their best efforts to make up for the delays in clinical trials in various therapeutic areas, while taking into consideration the burden on medical institutions and others, so that new drugs can be made available to patients who are waiting for them as soon as possible.

We, the pharmaceutical industry, will continue to work in close collaboration with government agencies and other related parties to bring the new coronavirus infection under control as soon as possible and to save as many lives as possible.

(From the January 8, 2021 Pharmaceutical Manufacturers Association news release)